Trials / Completed
CompletedNCT03870503
Carbetocin Versus Oxytocin Plus Sublingual Misoprostol in the Management of Atonic Postpartum Hemorrhage
Carbetocin Versus Oxytocin Plus Sublingual Misoprostol in the Management of Atonic Post-partum Hemorrhage (PPH) After Vaginal Delivery: a Randomized Controlled Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 135 (actual)
- Sponsor
- Aswan University Hospital · Academic / Other
- Sex
- Female
- Age
- 20 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to compare the effectiveness and safety of carbetocin vs. oxytocin plus sublingual misoprostol in the management of atonic postpartum hemorrhage (PPH)after vaginal delivery.
Detailed description
The first cause of hemorrhage at the time of delivery is uterine atony; therefore, there is general agreement that active management of the third stage of labor is recommended. Oxytocin is the most widely used uterotonic agent but has a half-life of only 4-10 min, that is why it is better administered as a continuous intravenous infusion to achieve sustained uterotonic activity. Carbetocin is a synthetic long-acting oxytocin agonistic analog with prolonged half-life prolonging its pharmacological effects. Its prolonged uterine activity may theoretically offer advantages over oxytocin in the management of the third stage of labor. The side-effect profile of carbetocin was not found to be different from that of Oxytocin but may prove to be advantageous when compared to Syntometrine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | oxytocin | The patient will be received oxytocin 20 IU by intravenous infusion |
| DRUG | oxytocin plus misoprostol | The patient will be received oxytocin 20 IU by intravenous infusion plus 400 mic gm sublingual misoprostol |
| DRUG | Carbetocin | The patient received Carbetocin 100 mic gm |
Timeline
- Start date
- 2019-04-01
- Primary completion
- 2021-06-30
- Completion
- 2021-08-01
- First posted
- 2019-03-12
- Last updated
- 2021-09-29
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT03870503. Inclusion in this directory is not an endorsement.